Multiple Myeloma
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Conference Coverage
Debate: Should smoldering myeloma be treated?
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
Article
ClonoSEQ Testing for Minimal Residual Disease in Multiple Myeloma: Cleveland VA Experience And Cost Analysis
Article
Comparing Outcomes and Toxicities With Standard and Reduced Dose Melphalan in Autologous Stem Cell Transplant Patients With Multiple Myeloma
News
FDA approves elranatamab for multiple myeloma
Elranatamab previously received Breakthrough Therapy Designation for relapsed or refractory multiple myeloma.
News
FDA OKs talquetamab, a first-in-class myeloma tx
Accelerated approval has been granted by the FDA to talquetamab-tgvs, a bispecific antibody, for patients with myeloma who have undergone at least...
News
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
News
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
